



## **THE PRITZKER NEUROPSYCHIATRIC DISORDERS RESEARCH CONSORTIUM RENEWS AND EXPANDS ACCESS TO INGENUITY PATHWAYS ANALYSIS TO AID EFFORTS TO IDENTIFY NOVEL TREATMENT TARGETS**

**Redwood City, CA – January 8, 2008** – Ingenuity Systems, the leading provider of information solutions to help life science researchers generate insights from biological and chemical information, is pleased to announce that the Pritzker Neuropsychiatric Disorders Research Consortium (PNDRC) has renewed and expanded its licensing agreement for access to the Ingenuity Pathways Analysis (IPA) software application, assisting the PNDRC's efforts to understand neuropsychiatric disorders. Consortium members will utilize the newest release of IPA to illustrate significant differences in gene expression and to determine impact in neuronal pathways, circuits, and target systems.

The PNDRC focuses on the discovery of neurobiological and genetic causes of severe psychiatric disorders such as major depression, manic-depressive illness or bipolar disorder, and schizophrenia, with a concerted effort to identify novel targets for the treatment of these diseases. IPA plays a significant role in these research programs by enabling the creation and comprehensive analysis of customized pathways, which can then help correlate gene expression profiles to functions, diseases, pathways, and molecular mechanisms in order to better elucidate novel targets.

### **About Pritzker Neuropsychiatric Disorders Research Consortium (PNDRC)**

The PNDRC is a collaborative research enterprise comprised of several academic institutions including scientific groups at the University of Michigan, Weill Medical College of Cornell University, Stanford University, University of California at Irvine, and the University of California at Davis. The PNDRC is focused on understanding the neurobiology and genetics of mood disorders and schizophrenia. It is conducting studies on human post-mortem tissue, blood samples from isolated populations, and various animal models, to identify altered profiles of gene expression in blood or brain circuits associated with these disorders. Its aim is to uncover the causes of these illnesses, identify novel targets for their diagnosis, treatment and prevention and to ensure that applications of these discoveries are utilized to the fullest extent possible. More information is available at <http://www.pritzkerneuropsych.org/>

### **About Ingenuity Systems®**

Ingenuity Systems is a leading provider of information solutions to help life science researchers generate insights from biological and chemical information. Ingenuity Systems is recognized as a technology leader, providing complete solutions for researchers to better understand the complex systems foundational to human health and disease. Today, Ingenuity's solutions are used by thousands of researchers at hundreds of leading pharmaceutical, biotechnology, and academic research institutions worldwide. Ingenuity was founded in 1998 and is headquartered in Redwood City, California with offices in Germany, Switzerland, France, the United Kingdom, and Japan. [www.ingenuity.com](http://www.ingenuity.com).

### **Contact:**

Heidi Bullock  
Director, Marketing  
Ingenuity Systems  
650.381.5150

# # #